Genmab A/S (NASDAQ:GMAB) Shares Gap Down - Time to Sell?

Genmab A/S (NASDAQ:GMAB - Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $21.77, but opened at $21.13. Genmab A/S shares last traded at $21.27, with a volume of 278,200 shares.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Truist Financial lowered their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research report on Tuesday, March 11th. Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research report on Thursday, February 13th. Finally, Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Genmab A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Price Performance

The stock has a 50-day simple moving average of $20.02 and a 200-day simple moving average of $20.65. The stock has a market cap of $13.98 billion, a PE ratio of 12.53, a P/E/G ratio of 2.65 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. As a group, equities research analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Several institutional investors and hedge funds have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Headlands Technologies LLC lifted its stake in shares of Genmab A/S by 1,525.0% in the first quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock worth $31,000 after acquiring an additional 1,464 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in shares of Genmab A/S by 124.3% in the first quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock worth $38,000 after acquiring an additional 1,070 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Finally, Barclays PLC lifted its stake in shares of Genmab A/S by 1,072.8% in the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after acquiring an additional 2,285 shares in the last quarter. Hedge funds and other institutional investors own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.